Pierre Fabre Pharmaceuticals Submits Type A Meeting Request to U.S. Food and Drug Administration (FDA) for Tabelecleucel Biologic License Application (BLA)
SECAUCUS, N.J., March 3, 2026 /PRNewswire/ -- On March 2, 2026, Pierre Fabre Pharmaceuticals, Inc., submitted a request to the...
Read moreDetails